Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued to investors on Monday.
A number of other research analysts have also recently weighed in on the company. BidaskClub upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, February 8th. Royal Bank of Canada began coverage on Aimmune Therapeutics in a report on Wednesday, February 7th. They issued an “outperform” rating and a $55.00 target price on the stock. Roth Capital lifted their target price on Aimmune Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Credit Suisse Group set a $45.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, January 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Aimmune Therapeutics has a consensus rating of “Buy” and a consensus target price of $57.25.
Shares of Aimmune Therapeutics (NASDAQ AIMT) opened at $37.84 on Monday. Aimmune Therapeutics has a fifty-two week low of $15.97 and a fifty-two week high of $40.65. The stock has a market capitalization of $1,975.03, a price-to-earnings ratio of -16.10 and a beta of -0.82.
In other Aimmune Therapeutics news, insider Douglas T. Sheehy sold 1,906 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $38.66, for a total value of $73,685.96. Following the transaction, the insider now directly owns 1,906 shares of the company’s stock, valued at $73,685.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mary M. Rozenman sold 6,592 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $35.36, for a total value of $233,093.12. The disclosure for this sale can be found here. Insiders sold 134,294 shares of company stock worth $5,097,144 over the last three months. 17.59% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the business. MYDA Advisors LLC purchased a new position in Aimmune Therapeutics in the fourth quarter valued at about $378,000. Alliancebernstein L.P. raised its position in Aimmune Therapeutics by 109.5% in the fourth quarter. Alliancebernstein L.P. now owns 1,400,281 shares of the biotechnology company’s stock valued at $52,959,000 after purchasing an additional 731,927 shares during the period. Geode Capital Management LLC raised its position in Aimmune Therapeutics by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 264,577 shares of the biotechnology company’s stock valued at $10,006,000 after purchasing an additional 16,804 shares during the period. Carillon Tower Advisers Inc. purchased a new position in Aimmune Therapeutics in the fourth quarter valued at about $58,838,000. Finally, First Republic Investment Management Inc. purchased a new position in Aimmune Therapeutics in the fourth quarter valued at about $202,000. 73.14% of the stock is currently owned by institutional investors.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.